We are live on ! Find out more
AC

Aisling Capital Portfolio holdings

AUM $45.3M
1-Year Est. Return 15.24%
This Fund
S&P 500
This Quarter Est. Return
+34.58%
1 Year Est. Return
-15.24%
3 Year Est. Return
+386.13%
5 Year Est. Return
+981.36%
10 Year Est. Return
–
AUM
$660M
AUM Growth
+$144M
Cap. Flow
+$26.5M
Cap. Flow %
4.02%
Top 10 Hldgs %
82.46%
Holding
21
New
3
Increased
1
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
ADMA icon
ADMA Biologics
ADMA
+$41.3M
2
DERM
Dermira, Inc.
DERM
+$18.4M
3
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$16.3M
4
LITS
Lite Strategy Inc
LITS
+$1.65M

Top Sells

Rank Stock Value
1
DRTX
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
+$25.7M
2
AMBI
Ambit Biosciences Corp
AMBI
+$25.4M

Sector Composition

Rank Sector Weight
1 Healthcare 82.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESPR
1
DELISTED
Esperion Therapeutics
ESPR
$83.1M 12.6%
2,054,594
– –
CEMP
2
DELISTED
Cempra, Inc.
CEMP
$77.4M 11.74%
3,293,060
– –
ZLTQ
3
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$72.5M 10.99%
2,597,742
– –
CMRX
4
DELISTED
Chimerix, Inc.
CMRX
$61.3M 9.3%
1,522,943
– –
CTLT
5
DELISTED
CATALENT, INC.
CTLT
$49.1M 7.44%
1,761,225
– –
TTOO
6
DELISTED
T2 Biosystems, Inc
TTOO
$48.5M 7.36%
505
– –
ARAV
7
DELISTED
Aravive, Inc. Common Stock
ARAV
$44.8M 6.79%
332,428
– –
LOXO
8
DELISTED
Loxo Oncology, Inc
LOXO
$40.6M 6.15%
3,452,493
– –
ADMA icon
9
ADMA Biologics
ADMA
$1.98B
$40.3M 6.11%
+3,608,171
New +$41.3M
PRTK
10
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$26.3M 3.99%
+682,680
New +$16.3M
ASXC
11
DELISTED
Asensus Surgical, Inc.
ASXC
$24.3M 3.68%
641,217
– –
DERM
12
DELISTED
Dermira, Inc.
DERM
$20M 3.03%
+1,102,046
New +$18.4M
PTX
13
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$18.9M 2.86%
201,000
– –
SRNE
14
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$17.8M 2.69%
1,763,500
– –
AGRX
15
DELISTED
Agile Therapeutics
AGRX
$13.3M 2.02%
1,086
– –
XENT
16
DELISTED
Intersect ENT, Inc
XENT
$6.49M 0.98%
350,000
– –
EVAR
17
DELISTED
Lombard Medical, Inc.
EVAR
$5.76M 0.87%
886,363
– –
ROKA
18
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$4.95M 0.75%
112,242
– –
LITS
19
Lite Strategy Inc
LITS
$34.7M
$4.32M 0.65%
50,590
+12,500
+33% +$1.65M
DRTX
20
DELISTED
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
– –
-2,030,175
Closed -$25.7M
AMBI
21
DELISTED
Ambit Biosciences Corp
AMBI
– –
-1,650,156
Closed -$25.4M

Similar funds

SCPM
Sagard Capital Partners Management New York $46.7M AUM 23.43% 1-Year Est. Return
ZIM
ZPR Investment Management Orange City, Florida $46.8M AUM 2.45% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return
INL
IPC/NYCG LLC New York $43.3M AUM 61.41% 1-Year Est. Return
CP
Clover Partners Dallas, Texas $43.1M AUM 4.09% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
JCM
Julex Capital Management Wellesley, Massachusetts $42.4M AUM 9.78% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return

Aisling Capital's Q4 2014 Portfolio in Review

As of Q4 2014, Aisling Capital held 21 positions worth $660M, up 28% from $516M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Aisling Capital deployed $26.5M of net new capital in Q4 2014, opening 3 new positions and adding to 1 existing holding. Its largest new stake was ADMA Biologics: 3,608,171 shares worth $40.3M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 72% a quarter earlier.

On the sell side, the most notable exit was DURATA THERAPEUTICS INC COM STK (DE), an estimated $25.7M sold.

  • Aisling Capital's largest Q4 2014 buy was ADMA Biologics: 3,608,171 shares worth $40.3M.
  • Aisling Capital added most to Lite Strategy Inc in Q4 2014, an estimated $1.65M increase.
  • Aisling Capital fully exited DURATA THERAPEUTICS INC COM STK (DE) in Q4 2014, selling an estimated $25.7M.
  • Aisling Capital's ten largest holdings make up 82% of its $660M portfolio in Q4 2014.
  • Aisling Capital opened 3 new positions and closed 2 in Q4 2014.
  • Aisling Capital's portfolio value rose 28% quarter-over-quarter to $660M.

Based on Aisling Capital's 13F filing for Q4 2014, filed 13 Feb 2015.